We are a global, clinical stage biopharmaceutical company developing innovative therapeutics in the fields of immuno-oncology and inflammatory diseases.

Our discovery and development programs are driven by unmet medical and patient needs and strong science supported by our two patented transgenic mouse platforms for generating fully human monoclonal antibodies. We focus on developing an innovative pipeline of Next-Gen therapeutics through our internal R&D programs, collaborations with co-discovery and co-development partners and select acquisitions.

With operations in the US, the Netherlands, and China, we also license our core platform technology to other companies and academic institutions globally.